Where hope and uncertainty meet: A cutting-edge cancer developer's winding road

Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.

By Alexandra Pecci • May 9, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Pharma's solution to the digital advertising dilemma? Storytelling

Peter Shin, vice president of Client Services at Sonic Health, says quality storytelling, rather than trendy content, is central to a digital advertising strategy.

By Karissa Waddick • May 5, 2022

Ultra-sensitive tests bring biomarkers into the drug development forefront

An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.

By Michael Gibney • May 5, 2022

Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine

After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.

By Taren Grom , Karissa Waddick • May 4, 2022

One company's failed drug is this company's 'jewel'

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

By Meagan Parrish • May 2, 2022

The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters

The next big innovation wave is out there, and as pharmas expect massive losses without enough internal R&D to fill those shoes, smaller biotechs beckon.

By Michael Gibney • April 28, 2022

Mouse vs. machine: Using AI to solve the animal testing model in pharma

Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

By Michael Gibney • April 26, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022

Dispelling the 5 myths of biopharma brand planning

Many biopharma marketers have worked for more than one company during their career. 

April 25, 2022

From the fringes to the forefront — the mRNA era has taken hold of pharma

A look at what’s next for the industry’s buzziest technology.

By Kim Ribbink • April 22, 2022

Woman of the Week: Aura Biosciences' Dr. Elisabet de los Pinos

Dr. Elizabet de los Pinos, CEO and founder of Aura Biosciences, had a dream at a young age to change the course of cancer treatment and understand the underlying DNA of the disease.

By Taren Grom • April 20, 2022

With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

What now? Alzheimer's drugmakers ponder the path to approval

Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

By Kelly Bilodeau • April 14, 2022

Woman of the Week: iSpecimen's Jill Mullan

Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

By Taren Grom • April 13, 2022

Biotech goes Hollywood

A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

By Taren Grom • April 13, 2022

'Bootcamp' helps rare disease advocates learn the ropes of drug development

Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

By Kim Ribbink • April 12, 2022

Optinose CEO senses big opportunities for the company's nasal delivery device

Peter Miller explains how a repackaged sinus drug has won late-stage clinical success.

By Jared Whitlock • April 11, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

Seeing yourself at the top: Alnylam CEO on why representation matters

Dr. Yvonne Greenstreet became just the sixth woman in the world to head up a biopharma company with a market cap of more than $5 billion when she took on the role of CEO in January.

By Alexandra Pecci • April 6, 2022

An analyst turned pharma CEO learns the art of operations

Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

By Jared Whitlock • April 5, 2022

Clinical trial recruitment hits the local pharmacy counter

CVS Health's partnership with clinical trial software company Medable is designed to make recruitment easier for patients and drug makers alike.

By Kelly Bilodeau • April 5, 2022

Time-saving tech lights Alcon's path into digital innovation

Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

By Kim Ribbink • April 4, 2022

Sangamo has its finger on the next evolution of gene editing

Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

By Taren Grom • March 31, 2022

Woman of the Week: Daré Bioscience's Sabrina Martucci Johnson

The CEO is setting a path to transform women’s health at an opportune time.

By Taren Grom • March 30, 2022